

# **Cancer Research Trust**

**ABN 33 906 785 987**

**Annual Report - 30 June 2023**

**Cancer Research Trust**

**Contents**

**30 June 2023**

Directors' report	2
Statement of profit or loss and other comprehensive income	4
Statement of financial position	5
Statement of changes in equity	6
Statement of cash flows	7
Notes to the financial statements	8
Directors' declaration	13
Auditor's Independence Declaration Under Section 60-40 of the Australian Charities and Not-For-Profits Commission Act 2012	14
Independent audit report	15

**Cancer Research Trust  
Directors' report  
30 June 2023**

The Directors submit the Trustee's report, together with the financial statements, on the Trust for the year ended 30 June 2023.

**Directors**

The following persons were Directors of the Trustee during the whole of the financial year and up to the date of this report, unless otherwise stated:

The names of the Directors of Cancer Research Fund Pty Ltd, the Trustee of the Cancer Research Trust, in office during the period and until the date of this report are:

Peter Leonhardt  
Peter Mansell  
Willem Lesterhuis  
Ruth Ganss

**Principal activities, review and results of operations of the Trust**

Cancer Research Fund Pty Ltd (CRF or the Trustee) acts as Trustee of the Cancer Research Trust (the Trust).

The Trust is endorsed as a Health Promotion Charity and has Deductible Gift Recipient status and is established:

- (1) To support and promote cancer research and education at a state, national and international level, and
- (2) To establish, maintain and administer a public fund or funds for any charitable purposes in relation to cancer research.

Pursuant to the Constitution of CRF and the Trust Deed:

- (1) The Trust is managed by the board of directors the Trustee (Board)
- (2) The Board is to appoint an external national/international scientific committee to advise and assist the Board and facilitate and oversee the peer review process.
- (3) The Trust Deed includes provisions:
  - (a) To ensure proper corporate governance;
  - (b) For the utilisation of an international peer review process for the assessment and allocation of grants from the Trust;
  - (c) That all research conducted pursuant to grants from the Trust be conducted in accordance with the Joint NHMRC/AVCC Statement and Guidelines on Research Practice (1991) or such other guidelines as may replace those guidelines;
  - (d) For the establishment of a nominations committee to call for and assess suitable appointees to the board to replace retirees;
  - (e) That the assets transferred to the Trust on settlement be invested prudently with the intention that the capital not be distributed as grants for at least 10 years of the Trust's existence. This date was passed on 28 April 2019;
  - (f) For the income to be applied towards the objects of the Trust; and
  - (g) Part of the income be used to establish and maintain an annual post-doctoral fellowship for a Western Australian based person to undertake cancer research and education at WEHI, with that person selected in accordance with the protocols published by the NHMRC.

The Trust Fund is made up of:

- (1) The CRI Fund being that part of the Trust Fund represented by the proceeds from realisation of the initial Trust Assets;
- (2) The Gift Fund (that part made up of public gifts of money or property made for Trust Purposes);
- (3) Public funds from donations, gifts, endowments, trust distributions, and any form of financial assistance from the public;
- (4) All money, investments and assets accepted by the Trustee; and
- (5) All accreditations and accumulations of income

The investment policy of the Trust is that the CRI Fund is to be invested prudently and responsibly. The current policy of the CRT Board is to maintain the Trust capital intact in real terms.

The distribution policy of the Trust is that any person or body corporate can apply to receive funding for an eligible project (a project that advances the Trust purposes). The current policy is to call for applications which are assessed on a competitive review basis. The applications are to be assessed by the scientific committee in accordance with the NHMRC Project Grants Peer Review Process for Funding 2009. The scientific committee is to advise the Trustee in writing of approved funding. The Trustee has the absolute discretion to decline funding.

**Cancer Research Trust  
Directors' report  
30 June 2023**

During year ended 30 June 2023, grants, scholarships and honorariums to a value of \$2,000,000 (2022: \$2,600,000) were funded.

The Board appointed JB Were as the investment advisor and portfolio manager after having considered:

- (1) Qualifications and Perth presence;
- (2) Governance;
- (3) Portfolio construction and investment allocation;
- (4) Forecast returns and risk profile;
- (5) Timing; and
- (6) Fees

JB Were has presented periodic reports and recommendations to the Investment Committee and the Board for consideration and acceptance or otherwise.

For the year ended 30 June 2023, the CRI Fund:

- (1) generated a net loss of \$997,858 before realised and unrealised profits on investments and after grants, scholarships and honorariums of \$2,000,000 (2022: \$1,167,227 loss after grants, scholarships and honorariums of \$2,600,000) from the available capital base of \$21,247,732 (2022: \$21,247,732);
- (2) realised profits on the investments sold during the year of \$1,029,995 (2022: profit \$1,073,203); and
- (3) had unrealised profit on the investment portfolio at 30 June 2023 of \$925,132 (2022: loss \$4,940,650).

**Corporate governance**

The board of directors of the Trustee ("Board") is responsible for corporate governance of the Trust.

All directors appointed to CRF must comply with the terms of the Settlement and the Constitution of CRF, which require that the Trustee must ensure that the principles of good governance are applied to all deliberations which occur under the Trust and by all advisory committees established under the Trust.

The Board established the Investments Committee to establish, review and monitor an investment strategy for management of the Trust's funds and make recommendations to the Board in conjunction with the appointed investment advisor.

The Board, following recent changes in membership, has moved to reconstitute the Scientific Committee that provides advice in relation to applications for grants and approvals of funding.

A Nominations Committee will be formed if and when required to assist the Board in reviewing the selection and appointment of directors and to regularly review and evaluate the performance of the Board.

Signed in accordance with a resolution of the directors of the Trustee.



---

Peter Leonhardt  
Director

6<sup>th</sup> December 2023  
Perth

**Cancer Research Trust**  
**Statement of profit or loss and other comprehensive income**  
**For the year ended 30 June 2023**

	<b>2023</b>	<b>2022</b>
	<b>\$</b>	<b>\$</b>
<b>Revenue</b>		
Interest earned on funds at bank and on term deposits	1,202	39
Distributions received or receivable from monies invested in managed funds	720,831	982,890
Dividends received or receivable from investments in listed securities	336,664	474,978
Realised profits on investments	1,029,995	1,073,203
Unrealised profit/(losses) on investments	925,132	(4,940,650)
	<b>3,013,824</b>	<b>(2,409,540)</b>
<b>Expenses</b>		
Bank charges	(120)	(120)
Accounting and secretarial fees	(12,650)	(15,925)
Audit fees	(4,200)	(4,000)
ASIC fees	(290)	(276)
Consultants	(18,863)	(60,769)
Insurance	(6,504)	(6,095)
Investment management fees	(128,709)	(146,694)
Promotion	(1,045)	(1,605)
Legal fees	-	(1,500)
Grants, scholarships and honorariums	(2,000,000)	(2,600,000)
Travel and entertainment	(2,028)	(2,877)
Total expenses	<b>(2,174,409)</b>	<b>(2,839,861)</b>
<b>Surplus/(deficit) before income tax benefit</b>	<b>839,415</b>	<b>(5,249,401)</b>
Income tax benefit	117,854	214,727
<b>Surplus/(deficit) after income tax benefit for the year attributable to the members of Cancer Research Trust</b>	<b>957,269</b>	<b>(5,034,674)</b>
Other comprehensive income for the year, net of tax	-	-
<b>Total comprehensive income for the year attributable to the members of Cancer Research Trust</b>	<b>957,269</b>	<b>(5,034,674)</b>
On income account	(997,858)	(1,167,227)
On capital account	1,955,127	(3,867,447)
	<b>957,269</b>	<b>(5,034,674)</b>

*The above statement of profit or loss and other comprehensive income should be read in conjunction with the accompanying notes*

**Cancer Research Trust**  
**Statement of financial position**  
**As at 30 June 2023**

	<b>Note</b>	<b>2023</b> \$	<b>2022</b> \$
<b>Assets</b>			
<b>Current assets</b>			
Cash and cash equivalents	3	1,753,012	2,815,493
Trade and other receivables	4	528,132	837,093
Tax asset	5	117,854	214,727
Other	6	3,150	3,008
<b>Total current assets</b>		<b>2,402,148</b>	<b>3,870,321</b>
<b>Non-current assets</b>			
Financial assets	7	34,101,475	31,676,589
<b>Total non-current assets</b>		<b>34,101,475</b>	<b>31,676,589</b>
<b>Total assets</b>		<b>36,503,623</b>	<b>35,546,910</b>
<b>Liabilities</b>			
<b>Current liabilities</b>			
Trade and other payables	8	45,376	45,932
<b>Total current liabilities</b>		<b>45,376</b>	<b>45,932</b>
<b>Total liabilities</b>		<b>45,376</b>	<b>45,932</b>
<b>Net assets</b>		<b>36,458,247</b>	<b>35,500,978</b>
<b>Equity</b>			
Contributed capital	9	21,247,732	21,247,732
Retained surpluses		15,210,515	14,253,246
<b>Total equity</b>		<b>36,458,247</b>	<b>35,500,978</b>

*The above statement of financial position should be read in conjunction with the accompanying notes*

**Cancer Research Trust**  
**Statement of changes in equity**  
**For the year ended 30 June 2023**

	<b>Contributed capital \$</b>	<b>Retained profits \$</b>	<b>Total equity \$</b>
Balance at 1 July 2021	21,247,732	19,287,920	40,535,652
Deficit after income tax benefit for the year	-	(5,034,674)	(5,034,674)
Other comprehensive income for the year, net of tax	-	-	-
<b>Total comprehensive income for the year</b>	<b>-</b>	<b>(5,034,674)</b>	<b>(5,034,674)</b>
<b>Balance at 30 June 2022</b>	<b>21,247,732</b>	<b>14,253,246</b>	<b>35,500,978</b>

	<b>Contributed capital \$</b>	<b>Retained profits \$</b>	<b>Total equity \$</b>
Balance at 1 July 2022	21,247,732	14,253,246	35,500,978
Surplus after income tax benefit for the year	-	957,269	957,269
Other comprehensive income for the year, net of tax	-	-	-
<b>Total comprehensive income for the year</b>	<b>-</b>	<b>957,269</b>	<b>957,269</b>
<b>Balance at 30 June 2023</b>	<b>21,247,732</b>	<b>15,210,515</b>	<b>36,458,247</b>

*The above statement of changes in equity should be read in conjunction with the accompanying notes*

**Cancer Research Trust**  
**Statement of cash flows**  
**For the year ended 30 June 2023**

	<b>Note</b>	<b>2023</b> <b>\$</b>	<b>2022</b> <b>\$</b>
<b>Cash flows from operating activities</b>			
Interest and trust distributions		981,011	1,240,230
Dividends received		341,087	373,917
Grants, research and scholarships paid		(2,000,000)	(2,787,500)
Payments to suppliers		(136,956)	(207,747)
Refund of franking credits		214,727	90,129
<b>Net cash used in operating activities</b>		<b>(600,131)</b>	<b>(1,290,971)</b>
<b>Cash flows from investing activities</b>			
Investments		(462,350)	2,921,293
<b>Net cash from/(used in) investing activities</b>		<b>(462,350)</b>	<b>2,921,293</b>
<b>Net cash from financing activities</b>		<b>-</b>	<b>-</b>
<b>Net increase/(decrease) in cash and cash equivalents</b>		<b>(1,062,481)</b>	<b>1,630,322</b>
<b>Cash and cash equivalents at the beginning of the financial year</b>		<b>2,815,493</b>	<b>1,185,171</b>
<b>Cash and cash equivalents at the end of the financial year</b>	<b>3</b>	<b>1,753,012</b>	<b>2,815,493</b>

*The above statement of cash flows should be read in conjunction with the accompanying notes*



**Cancer Research Trust**  
**Notes to the financial statements**  
**30 June 2023**

**Note 1. General information**

The financial report of Cancer Research Trust for the period ended 30 June 2023 was authorised for issue in accordance with a resolution of the directors of the Trustee on 6 December 2023.

The registered office of the trustee company and principal place of business is:

Unit 8  
110 Hay Street  
Subiaco WA 6008

A description of the nature of the Trustee's operations and its principal activities are included in the Directors' report, which is not part of the financial statements.

Cancer Research Trust is a charitable trust established by Trust Deed dated 28 April 2009. The Trustee was incorporated on 25 May 2009 for the purpose of acting as the Trustee of the Trust and is domiciled in Australia.

**Note 2. Significant accounting policies**

The principal accounting policies adopted in the preparation of the financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

**New or amended Accounting Standards and Interpretations adopted**

The Trustee has adopted all of the new or amended Accounting Standards and Interpretations issued by the Australian Accounting Standards Board ('AASB') that are mandatory for the current reporting period.

**Basis of preparation**

These general purpose financial statements have been prepared in accordance with the Australian Accounting Standards - Simplified Disclosures issued by the Australian Accounting Standards Board ('AASB'), the Australian Charities and Not-for-profits Commission Act 2012 and Western Australian legislation the Associations Incorporation Act 2015, the Charitable Collections Act 1946 and associated regulations, as appropriate for not-for profit oriented entities.

**Revenue recognition**

The Trustee recognises revenue as follows:

*Interest, Distribution, Dividend and Donation Income*

Interest, distribution, dividend and donation income are recognised when it is received or when the right to receive payment is established.

**Income tax**

As the Trustee is a charitable institution in terms of subsection 50-5 of the Income Tax Assessment Act 1997, as amended, it is exempt from paying income tax.

The current tax asset represents a refund of imputations credits.

**Current and non-current classification**

Assets and liabilities are presented in the statement of financial position based on current and non-current classification.

An asset is classified as current when: it is either expected to be realised or intended to be sold or consumed in the Trustee's normal operating cycle; it is held primarily for the purpose of trading; it is expected to be realised within 12 months after the reporting period; or the asset is cash or cash equivalent unless restricted from being exchanged or used to settle a liability for at least 12 months after the reporting period. All other assets are classified as non-current.

A liability is classified as current when: it is either expected to be settled in the Trustee's normal operating cycle; it is held primarily for the purpose of trading; it is due to be settled within 12 months after the reporting period; or there is no unconditional right to defer the settlement of the liability for at least 12 months after the reporting period. All other liabilities are classified as non-current.

**Note 2. Significant accounting policies (continued)**

Deferred tax assets and liabilities are always classified as non-current.

**Cash and cash equivalents**

Cash and cash equivalents includes cash on hand, deposits held at call with financial institutions, other short-term, highly liquid investments with original maturities of three months or less that are readily convertible to known amounts of cash and which are subject to an insignificant risk of changes in value.

**Trade and other receivables**

Other receivables are recognised at amortised cost, less any allowance for expected credit losses.

**Investments and other financial assets**

Investments and other financial assets are initially measured at fair value. Transaction costs are included as part of the initial measurement. Such assets are subsequently measured at either amortised cost or fair value depending on their classification. Classification is determined based on both the business model within which such assets are held and the contractual cash flow characteristics of the financial asset unless an accounting mismatch is being avoided. Equity instruments are measured at fair value with changes in fair value included in the profit and loss and are disclosed as unrealised gains or losses.

Financial assets are derecognised when the rights to receive cash flows have expired or have been transferred and the Trustee has transferred substantially all the risks and rewards of ownership. When there is no reasonable expectation of recovering part or all of a financial asset, its carrying value is written off. The gain or loss on the realisation of financial assets is measured as the disposal price less the initial fair value of the financial asset. The gain or loss is disclosed as realised in the profit or loss.

*Financial assets at amortised cost*

A financial asset is measured at amortised cost only if both of the following conditions are met: (i) it is held within a business model whose objective is to hold assets in order to collect contractual cash flows; and (ii) the contractual terms of the financial asset represent contractual cash flows that are solely payments of principal and interest.

*Investments*

Investments includes non-derivative financial assets with fixed or determinable payments and fixed maturities where the Trustee has the positive intention and ability to hold the financial asset to maturity. This category excludes financial assets that are held for an undefined period. Investments are carried at amortised cost using the effective interest rate method adjusted for any principal repayments. Gains and losses are recognised in profit or loss when the asset is derecognised or impaired.

**Trade and other payables**

These amounts represent liabilities for goods and services provided to the Trustee prior to the end of the financial year and which are unpaid. Due to their short-term nature they are measured at amortised cost and are not discounted. The amounts are unsecured and are usually paid within 30 days of recognition.

**Fair value measurement**

When an asset or liability, financial or non-financial, is measured at fair value for recognition or disclosure purposes, the fair value is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date; and assumes that the transaction will take place either: in the principal market; or in the absence of a principal market, in the most advantageous market.

Fair value is measured using the assumptions that market participants would use when pricing the asset or liability, assuming they act in their economic best interests. For non-financial assets, the fair value measurement is based on its highest and best use. Valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, are used, maximising the use of relevant observable inputs and minimising the use of unobservable inputs.

For equity instruments, the fair values have been determined based on closing quoted bid prices at the end of the reporting period.

**Goods and Services Tax ('GST') and other similar taxes**

Revenues, expenses and assets are recognised net of the amount of associated GST, unless the GST incurred is not recoverable from the tax authority. In this case it is recognised as part of the cost of the acquisition of the asset or as part of the expense.

**Note 2. Significant accounting policies (continued)**

Receivables and payables are stated inclusive of the amount of GST receivable or payable. The net amount of GST recoverable from, or payable to, the tax authority is included in other receivables or other payables in the statement of financial position.

Cash flows are presented on a gross basis. The GST components of cash flows arising from investing or financing activities which are recoverable from, or payable to the tax authority, are presented as operating cash flows.

Commitments and contingencies are disclosed net of the amount of GST recoverable from, or payable to, the tax authority.

**Comparative figures**

When required by accounting standards, comparative figures have been adjusted to conform to changes in presentation for the current financial year.

**Note 3. Current assets - cash and cash equivalents**

	<b>2023</b>	<b>2022</b>
	<b>\$</b>	<b>\$</b>
Cash at bank	1,753,012	2,815,493

**Note 4. Current assets - trade and other receivables**

	<b>2023</b>	<b>2022</b>
	<b>\$</b>	<b>\$</b>
Trust distribution, dividend & Interest income	496,313	767,123
Goods and services tax	31,819	69,970
	528,132	837,093

**Note 5. Current assets - tax asset**

	<b>2023</b>	<b>2022</b>
	<b>\$</b>	<b>\$</b>
Franking credits receivable	117,854	214,727

**Note 6. Current assets - other**

	<b>2023</b>	<b>2022</b>
	<b>\$</b>	<b>\$</b>
Prepayments	3,150	3,008

**Note 7. Non-current assets - financial assets**

	<b>2023</b>	<b>2022</b>
	<b>\$</b>	<b>\$</b>
Financial assets - Investments in equity instruments designated as at fair value through profit or loss	34,101,475	31,676,589

*Reconciliation*

Reconciliation of the fair values at the beginning and end of the current and previous financial year are set out below:

Opening fair value	31,676,589	38,363,860
Movement in period at cost	469,759	(2,819,824)
Realised profit on realisations	1,029,995	1,073,203
(Impairment)/Revaluation to fair value	925,132	(4,940,650)
Closing fair value	34,101,475	31,676,589

**Note 8. Current liabilities - trade and other payables**

	<b>2023</b>	<b>2022</b>
	<b>\$</b>	<b>\$</b>
Trade payables	35,729	36,286
Other payables	9,647	9,646
	45,376	45,932

**Note 9. Equity - contributed capital**

	<b>2023</b>	<b>2022</b>
	<b>\$</b>	<b>\$</b>
Contributed capital	21,247,732	21,247,732

  

	<b>2023</b>	<b>2022</b>
	<b>\$</b>	<b>\$</b>
Opening balance	21,247,732	21,247,732
Closing balance	21,247,732	21,247,732

**Note 10. Related party transactions**

Any person having authority and responsibility for planning, directing and controlling the activities of the entity, including any director of that entity, is considered key management personnel (KMP).

Related parties include KMP and other close family members of KMP and entities that are controlled by KMP individually or collectively with their close family member.

No compensation was paid to KMP and there were no other transactions with directors or other related parties.

**Note 11. Financial risk management**

The carrying amounts of for each category of financial instruments , measured in accordance with AASB 9:Financial Instruments are as follows:

	<b>Note</b>	<b>2023</b> \$	<b>2022</b> \$
<b>Financial assets</b>			
Financial assets at fair value through profit or loss			
Equity instruments (not held for trading)		23,521,373	23,411,936
Equity instruments - Fixed instrument securities		10,580,102	8,264,653
	7	34,101,475	31,676,589
Financial assets at amortised cost			
Cash and cash equivalents	3	1,753,012	2,815,493
Trade and other receivables	4	528,132	837,093
<b>Total financials assets</b>		<b>36,382,619</b>	<b>35,329,175</b>
	<b>Note</b>	<b>2023</b> \$	<b>2022</b> \$
<b>Financial liabilities</b>			
Financial liabilities at amortised costs			
Trade and other payables	8	45,376	45,932
<b>Total financial liabilities</b>		<b>45,376</b>	<b>45,932</b>

**Note 12. Events after the reporting period**

No matter or circumstance has arisen since 30 June 2023 that has significantly affected, or may significantly affect the Trustee's operations, the results of those operations, or the Trustee's state of affairs in future financial years.

**Cancer Research Trust**  
**Directors' declaration**  
**30 June 2023**

In accordance with a resolution of the directors of Cancer Research Fund Pty Ltd as Trustee for the Cancer Research Trust, I state that:

- the attached financial statements and notes comply with the Australian Accounting Standards - Simplified Disclosures, the Australian Charities and Not-for-profits Commission Act 2012 and Western Australian legislation the Associations Incorporation Act 2015, the Charitable Collections Act 1946 and associated regulations;
- the attached financial statements and notes give a true and fair view of the Trustee's financial position as at 30 June 2023 and of its performance for the financial year ended on that date; and
- there are reasonable grounds to believe that the Registered Entity will be able to pay the debts incurred on behalf of the Cancer Research Trust as and when they become due and payable.

On behalf of the Board and in accordance with subsection 60.15(2) of the *Australian Charities and Not-for-profit Commission Regulation 2013*.



---

Peter Leonhardt  
Director

6<sup>th</sup> December 2023  
Perth

**AUDITOR'S INDEPENDENCE DECLARATION  
UNDER SECTION 60-40 OF THE AUSTRALIAN CHARITIES  
AND NOT-FOR-PROFITS COMMISSION ACT 2012  
TO THE TRUSTEE OF THE  
CANCER RESEARCH TRUST  
ABN: 33 906 785 987**

I declare that, to the best of my knowledge and belief, during the year ended 30 June 2023 we have complied with the independence requirements of the Australian Charities and Not-For-Profits Commission Act 2012 and any applicable code of professional conduct in relation to the audit



**ACCRU<sup>+</sup> PERTH  
Chartered Accountants**



**GRAEME ROBERT JENNINGS  
Registered Company Auditor**

Date: // December 2023  
West Perth, WA

**INDEPENDENT AUDITOR'S REPORT  
TO THE TRUSTEE OF THE  
CANCER RESEARCH TRUST  
ABN: 33 906 785 987**

**Report on the Audit of the Financial Report**

Opinion

We have audited the financial report of Cancer Research Trust (the Trust), which comprises the Statement of Financial Position as at 30 June 2023, the Statement of Profit or Loss and Other Comprehensive Income, the Statement of Changes in Equity and Statement of Cash Flows for the year then ended, notes comprising a summary of significant accounting policies and other explanatory information, and the Trustee company's Declaration.

In our opinion, the accompanying financial report of Cancer Research Trust (the Trust) has been prepared in accordance with Div 60 of the *Australian Charities and Not-for-Profits Commission Act 2012* (ACNC Act), including:

- (i) giving a true and fair view of the Trust's financial position as at 30 June 2023 and of its financial performance for the year then ended; and,
- (ii) complying with Australian Accounting Standards AASB 1060: General Purpose Financial Statements – Simplified Disclosure for For-Profit and Not-For-Profit Tier 2 Entities and Division 60 of the *Australian Charities and Not-For-Profits Commission Regulation 2013*.

Basis for Opinion

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those Standards are further described in the *Auditor's Responsibilities for the Audit of the Financial Report* section of our report. We are independent of the Trust in accordance with the ACNC Act, the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants* (the Code) that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Emphasis of Matter

We draw attention to Note 1 to the financial report, which describes the basis of accounting. The financial report has been prepared for the purpose of fulfilling the Trustee's financial reporting responsibilities under the Australian Charities and Not-For-Profits Commission Act 2012. As a result, the financial report may not be suitable for another purpose. Our opinion is not modified in respect of this matter.



**INDEPENDENT AUDITOR'S REPORT  
TO THE TRUSTEE OF THE  
CANCER RESEARCH TRUST  
ABN: 33 906 785 987**

**Information Other than the Financial Report and Auditor's Report Thereon**

The trustee of the Cancer Research Trust is responsible for the other information. The other information comprises the information included in the Trustee's Report for the year ended 30 June 2023. Our opinion on the financial report does not cover the other information and accordingly we do not express any form of assurance conclusion thereon. In connection with our audit of the financial report, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial report or our knowledge obtained in the audit or otherwise appears to be materially mis-stated. If, based on the work we have performed, we conclude that there is a material mis-statement of this other information, we are required to report that fact. We have nothing to report in this regard.

**Responsibilities of the Trustee for the Financial Report**

The Trustee of the Trust is responsible for the preparation of the financial report that gives a true and fair view in accordance with Australian Accounting Standards – Simplified Disclosure and the *Australian Charities and Not-For-Profits Commission Act 2012* and for such internal control as the trustee determines is necessary to enable the preparation of the financial report that gives a true and fair view and is free from material mis-statement, whether due to fraud or error

In preparing the financial report, the trustee is responsible for assessing the Trust's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the trustee either intends to liquidate the Trust or to cease operations, or have no realistic alternative but to do so.

**Auditor's Responsibilities for the Audit of the Financial Report**

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material mis-statement, whether due to fraud or error, and to issue an Auditor's Report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with the Australian Auditing Standards will always detect a material mis-statement when it exists. Mis-statements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this financial report.

As part of an audit in accordance with the Australian Auditing Standards, we exercise professional judgement and maintain professional scepticism throughout the audit.

**INDEPENDENT AUDITOR'S REPORT  
TO THE TRUSTEE OF THE  
CANCER RESEARCH TRUST  
ABN: 33 906 785 987**

We also:

- Identify and assess the risks of material mis-statement of the financial report, whether due to fraud or error, design and perform audit procedures responsive to those risks; and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material mis-statement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, mis-representations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Trust's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the trustee.
- Conclude on the appropriateness of the trustee's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Trust's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our Auditor's Report to the related disclosures in the financial report or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our Auditor's Report. However, future events or conditions may cause the Trust to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial report, including the disclosures, and whether the financial report represents the underlying transactions and events in a manner that achieves fair presentation.

We communicate with the trustee regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.



**ACCRU<sup>+</sup> PERTH**  
**Chartered Accountants**



**G R JENNINGS**  
**Registered Company Auditor**

Date: 11 December 2023  
West Perth, WA